DIRS.INFO The most relevant business & tech news

☆ F.D.A. Approves New Obesity Drug That Will Compete With Wegovy
▼ + stars: | 2023-11-08 | by ( Gina Kolata | More About Gina Kolata | ) www.nytimes.com time to read: 1 min

The Food and Drug Administration on Wednesday approved an obesity drug from the company Eli Lilly that will be a direct competitor to the wildly popular Wegovy. The drug is called tirzepatide and will be sold under the name Zepbound. Patients who used tirzepatide lost an average of 18 percent of their body weight, according to the F.D.A., when it was taken at its highest dose in a drug trial. That’s compared with Wegovy, manufactured by Novo Nordisk, which produced an average 15 percent weight loss. approved Zepbound for people with obesity and for those who are overweight and have at least one obesity-related condition.

Persons: Eli Lilly, tirzepatide Organizations: Drug Administration, Novo Nordisk

☆ FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug
▼ + stars: | 2023-11-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

George Frey | ReutersThe Food and Drug Administration on Wednesday approved Eli Lilly 's blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S. The FDA said the approval was based on two of Eli Lilly's late-stage trials on tirzepatide, which evaluated its effects on weight loss after 72 weeks. Higher doses of the drug were associated with even more weight loss, with a 15-milligram dose leading to 22.5% weight loss on average. The bigger issue is that many insurance companies are dropping weight loss drugs from their plans. Preliminary data is already available: A recent late-stage trial found that Novo Nordisk's weight loss drug Wegovy reduced the risk of cardiovascular events such as heart attack and stroke by 20%.

Persons: George Frey, Eli Lilly, John Sharretts, Eli Lilly's, Wegovy, Lilly, Mike Mason, Eli Lilly Diabetes Organizations: Novo Nordisk, Pharmacy, Reuters, Food, Drug Administration, U.S, FDA's Center, Drug, FDA, Obesity Locations: Provo , Utah, U.S, United States

A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday. The U.S. Food and Drug Administration approved Eli Lilly's drug, named Zepbound. Zepbound is the latest diabetes drug approved for chronic weight management, joining Novo Nordisk's Wegovy, a high-dose version of its diabetes treatment Ozempic. Those with diabetes, who have a harder time losing weight, cut about 12%, or nearly 27 pounds (12 kilograms), the FDA said. Approved for weight loss in 2021, Wegovy helped people lose about 15% of their weight or 34 pounds (15 kilograms), according to study results.

Persons: Eli Lilly's, dieters, Zepbound, Wegovy, Fatima Cody Stanford, tirzepatide, pare, ”, Katherine Saunders, Eli Lilly, Mounjaro, Kelly Burns, Burns Organizations: U.S . Food, Drug Administration, Novo Nordisk's Wegovy, FDA, Massachusetts General Hospital, New York's Weill Cornell Medicine, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, Zepbound, Wegovy, Massachusetts, Boston, St . Petersburg , Florida

☆ How Ozempic Maker Novo Nordisk’s Very Danish Capitalism Fueled Its Success, and Its Stumbles
▼ + stars: | 2023-11-07 | by ( Sune Engel Rasmussen | Photographs Charlotte De La Fuente For The Wall Street Journal | ) www.wsj.com time to read: 1 min

BAGSVÆRD, Denmark—Every rank-and-file employee at drugmaker Novo Nordisk calls the chief executive by his first name, Lars. Hallways and offices fall silent around 5 p.m., when workers leave to pick up their children or commute home, many by bicycle. Fueled by blockbuster sales of drugs used for obesity, this very Danish company is now one of the world’s most valuable. As of Friday, the company’s market capitalization was roughly $439 billion—more than Pfizer, Lockheed Martin and Starbucks combined. In September, it overtook LVMH, the French luxury-goods firm, as Europe’s biggest company by market capitalization.

Persons: Lars, Lockheed Martin, LVMH Organizations: Denmark —, drugmaker Novo Nordisk, Pfizer, Lockheed, Starbucks, Europe’s Locations: BAGSVÆRD, Denmark, Danish

☆ EU proposal may accelerate pharma innovation decline, industry group says
▼ + stars: | 2023-11-06 | by ( Julia Payne | ) www.reuters.com time to read: +3 min

"Any changes to our incentives system would equally affect EU-based and foreign-based companies which bring medicines to the EU and, therefore, it would not put EU firms at a disadvantage," an EU Commission spokesperson said. Medication was the single biggest contributor to the EU’s trade surplus, with 235 billion euro ($252.13 billion) worth of exports in 2021. The EFPIA said small biotech companies have already moved to the United States and China. The Commission said its proposal would reduce new medicine approval times to 180 days from 400 days. Germany, Belgium and France would be the hardest hit by the proposed rules, the EFPIA said citing research by Dolon that it commissioned.

Persons: EFPIA, Lars Fruergaard Jorgensen, Jorgensen, Ozempic, " Jorgensen, Julia Payne, Lisa Shumaker Organizations: European Commission, European Federation of Pharmaceutical Industries, EU, Commission, Novo Nordisk, Thomson Locations: BRUSSELS, United States, China, Danish, Boston, U.S, Europe, EU, Germany, Belgium, France

☆ Wall Street is asking how weight-loss drugs will affect consumer giants — but it may be too early to tell
▼ + stars: | 2023-11-06 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +1 min

Photographer: Caitlin O'Hara/Bloomberg via Getty ImagesIf you listen to third-quarter corporate earnings calls, it might seem like everyone is taking weight-loss drugs. Delta Air Lines , PepsiCo , Philip Morris International and Darden Restaurants are just some of the companies that faced questions from analysts about how the drugs are affecting their bottom lines. While some analysts are making sweeping claims about how obesity drugs will reshape the industries they cover, the medicines are still in the early days. Known as GLP-1s, the drugs were first approved for diabetes and are now also being used for obesity. But even so, only a sliver of eligible people are actually taking the drugs at this point, said Goldman Sachs analyst Chris Shibutani.

Persons: Caitlin O'Hara, Philip Morris, it's, Nestle –, It's, Wegovy, Goldman Sachs, Chris Shibutani Organizations: PepsiCo Inc, Bloomberg, Getty, Delta Air Lines, PepsiCo, Philip, Philip Morris International, Darden, Hershey, Conagra, Nestle, Novo Nordisk Locations: Phoenix , Arizona, U.S, Novo

☆ Ozempic and other weight-loss drugs will power the anti-obesity market to 16-fold gains by 2030, Goldman Sachs says
▼ + stars: | 2023-11-04 | by ( George Glover | ) www.businessinsider.com time to read: +3 min

The anti-obesity market could become a $100 billion industry by 2030, Goldman Sachs predicts. The rise of GLP-1 weight loss drugs has meant big gains for Novo Nord Nordisk and Eli Lilly. AdvertisementAdvertisementThe anti-obesity market is primed for a massive surge over the next six years, according to Goldman Sachs. Such a gain would push its total valuation from $6 billion to as much as $100 billion. Meanwhile, Barclays and Berenberg have predicted the market's value could climb to $100 billion and $85 billion respectively.

Persons: Goldman Sachs, Eli Lilly, —, they're, Chris Shibutani, Morgan Stanley Organizations: Novo Nord Nordisk, Service, Denmark's Novo Nordisk, Barclays, Berenberg

☆ Top money manager bets on Novo Nordisk, calls it a better play than Eli Lilly in weight-loss drug space
▼ + stars: | 2023-11-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTop money manager bets on Novo Nordisk, calls it a better play than Eli Lilly in weight-loss drug spaceElizabeth Evans, Evans May Wealth Managing Partner, joins 'Fast Money' to talk her playbook in the weight-loss drug space, who are the winners and losers, what mass adoption means for other sectors and more.

Persons: Eli Lilly, Elizabeth Evans, Evans Organizations: Novo Nordisk

☆ The Ozempic effect has battered this weight loss stock, but Morgan Stanley says it's a top pick
▼ + stars: | 2023-11-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +4 min

Sequence gives subscribers access to GLP-1 medications such as Novo Nordisk's Wegovy and Ozempic. Schenk said the concern about the drop in WW's average revenue per user "seems overblown" and has created a buying opportunity for the stock. Stabilizing core business WW has been focused on stabilizing its core weight loss business. Both developments are a positive for WW's Sequence business. Schenk estimates that around 6 million current or lapsed WW subscribers would qualify for treatment with obesity medication.

Persons: Sima Sistani, Morgan Stanley, Lauren Schenk, Eli Lilly, Schenk, Lilly, Novo Organizations: International, Nordisk's Wegovy, FDA, 3Q, and Drug Administration, Novo Nordisk Locations: Friday's, Novo

☆ Obesity Drug Demand Outstrips Supply
▼ + stars: | 2023-11-02 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Diabetes drugs could become an effective way to treat behavioral issues and addiction. WSJ’s Daniela Hernandez breaks down the science on how they work and how they could change psychiatry forever. Photo illustration: Elizabeth SmelovEli Lilly ’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to a surge in demand. Whether there will be enough of the drug is a different question. Both Lilly and its competitor, Denmark’s Novo Nordisk , which makes Ozempic and its sister drug Wegovy, are struggling to meet skyrocketing demand for their medications.

Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov Eli Lilly ’, Mounjaro, Lilly Organizations: Drug Administration, Denmark’s, Denmark’s Novo Nordisk Locations: Denmark’s Novo

☆ Wegovy Maker Novo Nordisk’s Profit Surges on Weight-Loss-Drug Demand
▼ + stars: | 2023-11-02 | by ( Dominic Chopping | ) www.wsj.com time to read: 1 min

Diabetes drugs could become an effective way to treat behavioral issues and addiction. WSJ’s Daniela Hernandez breaks down the science on how they work and how they could change psychiatry forever. Photo illustration: Elizabeth SmelovWegovy maker Novo Nordisk reported soaring profit, boosted by blockbuster weight-loss drugs that have quickly made the Danish drugmaker Europe’s most valuable company. Surging demand for the drugs has supercharged the company’s stock price, tilted the scales of its home economy in Denmark and triggered a frenzy on Wall Street over how the treatments and others like it might affect other industries, including snack foods and airlines.

Persons: WSJ’s Daniela Hernandez, Elizabeth Smelov Organizations: Novo Nordisk Locations: Danish, Denmark

☆ Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
▼ + stars: | 2023-11-02 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. Michael Siluk | UCG | Getty ImagesNovo Nordisk said Thursday that its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months. "I would say from today, [the outcome will be] less than six months," Knudsen told CNBC's Julianna Tatelbaum on "Street Signs." watch nowEarlier Thursday, Novo Nordisk in its third-quarter earnings announced plans to get expanded approval from the FDA, but shared no timeline. "The SELECT study is, in an obese population with established cardiovascular disease, does Wegovy reduce cardiovascular risk?

Persons: Michael Siluk, Karsten Munk Knudsen, Knudsen, CNBC's Julianna Tatelbaum, " Knudsen, Novo Organizations: UCG, Getty, Novo Nordisk, U.S . Food, Drug Administration, CNBC, FDA, Novo Nordisk's Locations: U.S, Danish

☆ Novo Nordish and Eli Lilly cash in on blockbuster weight-loss drugs
▼ + stars: | 2023-11-02 | by ( Manav Tanneeru | Samantha Delouya | ) edition.cnn.com time to read: +2 min

New York CNN —As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly. On Thursday, Novo Nordisk, the Denmark-based company behind Ozempic and Wegovy, reported a 29% increase in sales to $8.4 billion for the third quarter. The pharmaceutical companies are two of the biggest beneficiaries of the recent weight-loss drug frenzy, with Novo Nordisk catapulting to Europe’s most valuable company in September. Novo Nordisk reported that its obesity care sales grew 174% in the first nine months of 2023, mainly driven by US demand. The success of Novo Nordisk and Eli Lilly’s drugs has inspired other companies to dive into the prescription weight-loss business, including WeightWatchers, now known as WW International.

Persons: Eli Lilly, Mounjaro, Wegovy, Novo, –, Eli Lilly’s Organizations: New, New York CNN, drugmakers Novo Nordisk, Novo Nordisk, Novo Nordisk catapulting, International Locations: New York, Denmark, United States, Novo

☆ Stock Market Today: Dow Closes 500 Points Higher; Apple, Starbucks Earnings in Focus
▼ + stars: | 2023-11-02 | by ( ) www.wsj.com time to read: +1 min

Bond yields fell significantly for a second day. Major stock indexes jumped. Its shares jumped after the coffee shop chain's earnings topped estimates. The vaccine maker fell more than 6% after reporting a sharp drop in profits. Benchmark 10-year Treasury yields fell below 4.7%, settling at 4.668%, after trading near 5% last week.

Persons: Stocks, Jerome Powell, Dow, Brent Organizations: Federal, Novo Nordisk, Fed, Bank of England, Starbucks

☆ Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly on Thursday said supply of its blockbuster diabetes drug Mounjaro has improved in the U.S. after months of widespread shortages. During an earnings call Thursday, Eli Lilly executives said the company experienced tight supply for Mounjaro throughout most of the third quarter. But U.S. product shipments of Mounjaro have recently increased, and inventory levels at U.S. drug wholesalers have improved, according to Eli Lilly CFO Anat Ashkenazi. Eli Lilly has also invested more than $3 billion to build two new manufacturing sites in its home state of Indiana. Eli Lilly's main rival in the weight loss drug space, Novo Nordisk , is still navigating its own supply constraints of diabetes drug Ozempic and obesity treatment Wegovy.

Persons: Eli Lilly, Mounjaro, Eli Lilly's, Anat Ashkenazi, Ashkenazi, David Ricks, Ricks, we're, Wegovy, Eli Lilly's Mounjaro Organizations: Novo Nordisk, Pharmacy, Food, Pfizer Locations: Provo , Utah, U.S, North Carolina, Indiana, Novo

☆ Stock Market News Today: Dow Gains 400 Points; Apple, Starbucks Earnings in Focus
▼ + stars: | 2023-11-02 | by ( ) www.wsj.com time to read: +1 min

Bond yields fell significantly for a second day. Major stock indexes jumped. Shares jumped after the coffee shop chain's earnings topped estimates. Roku shares rose some 30%. Benchmark 10-year Treasury yields fell below 4.7%, after trading near 5% last week.

Persons: Stocks, Jerome Powell, Dow, Brent Organizations: Federal, Novo Nordisk, Fed, Bank of England, Starbucks

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Novo Nordisk on Thursday reported record profits and sales for the third quarter, but said supplies of its hugely popular weight loss drug Wegovy would continue to be restricted. The Danish pharmaceutical giant posted third-quarter sales of 58.73 billion Danish krone ($8.34 billion), a 29% increase from the same period last year, driven by demand for its flagship Ozempic and Wegovy drugs in the U.S. The company has struggled to keep up with demand for Wegovy, an appetite-suppressing anti-obesity drug, forcing it to limit the number of patients able to begin treatment.

Persons: Wegovy, Elliot Smith Organizations: Novo Nordisk, U.S Locations: Danish

☆ Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Novo Nordisk on Thursday said 80% of U.S. patients with insurance coverage who take its highly popular weight loss treatment Wegovy are paying less than $25 a month for the drug. He estimated that about 50 million Americans with obesity could be eligible for Wegovy coverage under their health plans. Most patients have to take Wegovy for several months to see — and sustain — significant weight loss. Wegovy, for example, leads to 15% weight loss after 68 weeks, according to clinical trials on the drug. But Novo Nordisk is hoping that new data demonstrating the heart health benefits of Wegovy will put more pressure on insurers to cover the medication and similar weight loss treatments.

Persons: Doug Langa, Langa, Eli Lilly, Karsten Munk Knudsen, Wegovy Organizations: Novo Nordisk, balk, Novo Nordisk's, North, Nordisk, CNBC, U.S . Food, Drug Administration, National Institutes of Health Locations: U.S, Novo, North America

☆ Eli Lilly's rally on blowout Mounjaro sales signals a new leg higher for the stock
▼ + stars: | 2023-11-02 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

LLY YTD mountain Eli Lilly's year-to-date stock performance. Investors are understandably cheering the results, sending Eli Lilly shares higher by more than 4%. "Eli Lilly today is beginning its next leg of going up," Jim Cramer said during Thursday's Morning Meeting . The most important line item was Mounjaro sales, which cleared Wall Street's high bar. Excluding that divestiture and the $387 million in Covid antibody sales in the year-ago quarter, Eli Lilly's sales grew 24% on an annual basis — a highly respectable figure.

Persons: Eli Lilly, LLY, Mounjaro, it's, Eli Lilly's, Jim Cramer, Jim, It's, Novo's, Lilly, We're, Dave Ricks, Ricks, Trulicity, Anat Ashkenazi, Lilly —, Ashkenazi, Jim Cramer's, David Ricks, Eli Lilly Scott Mlyn Organizations: Drug Administration, FDA, Novo Nordisk, CNBC, Management, Dice Therapeutics, Therapeutics Locations: North, Concord , North Carolina, U.S, Indianapolis

☆ Mounjaro remains the single largest driver for Eli Lilly stock in the near term: Mizuho's Jared Holz
▼ + stars: | 2023-11-02 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMounjaro remains the single largest driver for Eli Lilly stock in the near term: Mizuho's Jared HolzJared Holz, Mizuho healthcare sector specialist, joins 'Squawk on the Street' to discuss what's driving Novo Nordisk and Eli Lilly stocks right now, Holz thoughts on Wegovy, and more.

Persons: Eli Lilly, Jared Holz Jared Holz Organizations: Novo Nordisk Locations: Mizuho

Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo Acquire Licensing RightsCOPENHAGEN, Nov 2 (Reuters) - Novo Nordisk (NOVOb.CO) on Thursday reported record sales and operating profits for the third quarter but said it would keep in place restrictions on supplies of its hugely popular Wegovy weight-loss drug. Wegovy sales totaled 9.6 billion Danish crowns ($1.36 billion) between July and September, up 28% from the previous quarter and up eight-fold from the same period last year. In August, Novo said the curbs on Wegovy supplies would most likely extend into 2024. Sales grew 29% year-on-year to 58.7 billion Danish crowns ($8.33 billion), while operating profit (EBIT) rose 33% to 26.9 billion, both in line with preliminary numbers released last month.

Persons: Tom Little, Wegovy, Novo, Eli Lilly, Jacob Gronholt, Pedersen, Terje Solsvik Organizations: Novo Nordisk, Danish, REUTERS, Rights, European Union, U.S . Food, Drug Administration, Thomson Locations: Copenhagen, Denmark, U.S, United States

LONDON/COPENHAGEN, Nov 2 (Reuters) - Global brewers AB InBev (ABI.BR) and Carlsberg (CARLb.CO) this week played down concerns among some investors that demand for weight-loss drugs may lead to a sharp drop in beer drinking. But AB InBev Chief Executive Michel Doukeris likened the concerns to others, such as how cannabis could disrupt various sectors, which he said were often short-lived. Some clinical trials on rodents have found treatment with GLP-1 agonists reduces alcohol consumption, eases symptoms of alcohol withdrawal and more. AB InBev has a big U.S. business, but earns more revenue in the Middle Americas and has a large footprint in countries like Brazil. Such emerging markets often have lower obesity rates, while weight-loss drugs are unlikely to be available or affordable there any time soon.

Persons: Nordisk's Wegovy, Michel Doukeris, Jacob Aarup, Andersen, Moritz Kronenberger, Janus Henderson, Tom O'Hara, O'Hara, Wegovy, Emma Rumney, Jacob Gronholt, Matthew Scuffham, Alexander Smith Organizations: Global, AB InBev, Carlsberg, Nordisk's, InBev, Reuters, Budweiser, World Health Organization, WHO, Germany's Union Investment, Brewers, Pedersen, Thomson Locations: COPENHAGEN, United States, Brazil, Asia, China, Danish, U.S, London, Copenhagen

☆ How Novo Nordisk makes its weight-loss drug Wegovy
▼ + stars: | 2023-11-01 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

[1/2] A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing RightsLONDON, Nov 1 (Reuters) - Novo Nordisk (NOVOb.CO) is spending billions of dollars to boost output and ease shortages of its hugely popular, highly effective weight-loss medicine Wegovy. FILL-FINISHNovo has hired Catalent (CTLT.N), a large U.S. contract drug manufacturer, to fill injection pens for Wegovy at two of that company's plants: in Brussels and in Bloomington, Indiana. Novo has also hired another U.S. firm, Thermo Fisher (TMO.N), as a Wegovy pen filler. COMPONENTSThe Wegovy injection pens for the U.S. market slightly differ from those sold in the European markets including Norway, Denmark, Germany and UK, where it has so far launched.

Persons: Victoria Klesty, Catalent, Novo, Wegovy, Maggie Fick, Josephine Mason, Tomasz Janowski Organizations: REUTERS, Novo Nordisk, U.S, Novo, Reuters, PCI Pharma Services, autoinjectors, West Pharmaceutical Services, Stevenato, SCHOTT Pharma, Thomson Locations: Oslo, Norway, August31, Victoria, Danish, Novo, Denmark, U.S, Brussels, Bloomington , Indiana, Greenville , North Carolina, Greenville, Germany, Europe, Swiss

☆ Never Mind Covid, Investors Want a Pfizer Obesity Pill
▼ + stars: | 2023-10-31 | by ( David Wainer | ) www.wsj.com time to read: +1 min

Pfizer says it hasn’t gotten the data on its experimental oral obesity medication. It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill. But the company’s silence on its experimental oral medication, danuglipron, during its earnings release Tuesday, is worrying Wall Street. “Not one mention [of danuglipron] in the prepared remarks from Pfizer,” noted Will Sevush , a healthcare strategist for Jefferies. Before today’s earnings, David Risinger , a Leerink Partners analyst, had written that Pfizer might even release data from its midstage study alongside the earnings results as soon as Tuesday.

Persons: hasn’t, Gabby Jones, Eli Lilly, ”, Will Sevush, Jefferies, David Risinger, Albert Bourla, TD Cowen, Steva Scala Organizations: Pfizer, The Wall, Novo Nordisk, Moderna, Partners

☆ Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
▼ + stars: | 2023-10-29 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +11 min

Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. All this goes on amid robust demand for Novo's semaglutide, which is sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, and Lilly's tirzepatide, which hopes to receive regulatory approval for weight loss this year. Orforglipron is an oral drug Eli Lilly is developing. It has several other compounds in the pipeline, but Suvannavejh expects the weight loss drug to receive increased attention. "This range would also be competitive with LLY's orforglipron [an oral GLP-1 drug] weight loss at day 28," Smith said.

Persons: Eli Lilly, Piper Sandler, Yasmeen Rahimi, Cantor Fitzgerald, Louise Chen, Lilly, Lilly's, Chen, Price, Kyle Rasbach, We've, Rasbach, Altimmune Altimmune, NASH, Piper's, Rahimi, Cantor's Chen, it's, Eli Lilly's Mounjaro, Goldman Sachs, Chris Shibutani, David Risinger, Risinger, Jonathan Wolleben, Wolleben, Orforglipron, Graig Suvannavejh, Suvannavejh, Thomas Smith, LLY's, Smith, Yale Jen, Jen Organizations: Novo Nordisk, Pfizer, Novo, pharma, Pfizer Pfizer, danuglipron, Therapeutics, Leerink, Mizuho Securities, Viking Therapeutics Viking Therapeutics, Laidlaw & Co Locations: Novo, GLP, Eventide

Search resuls for: "nordisk"

25 mentions found